Catalyst Pharmaceuticals Inc (CPRX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 45.19% | 56.27% | 49.22% | 48.54% | 49.52% |
| Operating profit margin | 21.80% | 47.54% | 37.20% | 34.69% | 31.11% |
| Pretax margin | 23.73% | 48.89% | 37.40% | 35.18% | 32.66% |
| Net profit margin | 17.93% | 38.79% | 28.03% | 62.97% | 31.16% |
Catalyst Pharmaceuticals Inc's profitability ratios have fluctuated over the past five years. The gross profit margin has shown some volatility, with a decline in 2023 compared to the previous years. This suggests a decrease in the percentage of revenue retained after deducting the cost of goods sold, which may be due to factors impacting the company's production costs or pricing strategies.
The operating profit margin has also fluctuated significantly, with a substantial decrease in 2023 compared to 2022. This indicates a lower percentage of revenue remaining after accounting for both cost of goods sold and operating expenses, which could reflect challenges in managing operational costs or generating revenue.
The pretax margin has followed a similar pattern of variability, with a notable drop in 2023 compared to the previous year. This ratio indicates the company's ability to control expenses relative to its total revenue before accounting for taxes. The decrease in 2023 suggests that Catalyst Pharmaceuticals Inc may have faced challenges in maintaining profitability before tax obligations.
The net profit margin, representing the company's bottom line profitability, has also shown variability over the years. The significant decrease in 2023 compared to 2022 is notable, indicating a lower percentage of revenue retained as net profit. This decline could be attributed to various factors such as increased expenses, lower revenues, or one-time charges impacting the company's earnings.
Overall, the analysis of these profitability ratios suggests that Catalyst Pharmaceuticals Inc has experienced fluctuations in its profitability performance over the past five years, highlighting the importance of closely monitoring and managing the company's financial performance to ensure long-term sustainability and growth.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 18.47% | 27.11% | 22.03% | 21.47% | 28.32% |
| Return on assets (ROA) | 15.19% | 22.12% | 16.60% | 38.98% | 28.36% |
| Return on total capital | 22.38% | 33.90% | 25.33% | 24.35% | 36.32% |
| Return on equity (ROE) | 18.41% | 27.65% | 19.09% | 44.21% | 36.37% |
Catalyst Pharmaceuticals Inc has shown consistent profitability over the past five years based on the profitability ratios provided.
1. Operating return on assets (Operating ROA) has fluctuated over the period, with a decrease in 2023 compared to the previous year. This ratio measures the company's ability to generate operating income from its assets, and its current value of 18.47% indicates that the company is efficiently utilizing its assets to generate operating profit.
2. Return on assets (ROA) has also demonstrated a fluctuating trend but remains positive and relatively stable over the years. ROA reflects the company's overall efficiency in generating profits from its total assets, with the current value at 15.19% highlighting Catalyst Pharmaceuticals Inc's ability to generate earnings from its assets.
3. Return on total capital has shown a similar fluctuating trend as the previous ratios, indicating the company's ability to generate returns for all its capital providers. The most recent value of 22.38% suggests that Catalyst Pharmaceuticals Inc is effectively utilizing both equity and debt to generate profits.
4. Return on equity (ROE) has also displayed fluctuations, showcasing the company's ability to generate returns for its shareholders. The latest value of 18.41% reflects the company's efficiency in generating profits relative to the shareholders' equity invested.
Overall, Catalyst Pharmaceuticals Inc has maintained a solid financial performance in terms of profitability ratios, although there have been fluctuations over the years. The values of these ratios indicate that the company has been effectively utilizing its assets and capital to generate profits for its stakeholders.